Secretary Clinton delivers remarks on creating an AIDS-free generation at the National Institutes of Health campus in Bethesda, Maryland. State Department( photo by Michael Gross)

Clinton külügyminiszter az AIDS-mentes világ megteremtését tűzte ki célul. Az összeállításban mellékelünk néhány gyógyszerekkel, gyógyászattal s az egészségüggyel foglalkozó új cikket, kiadványt is.


FACTSHEET:  The Path to an AIDS-Free Generation. U.S. Department of State Office of the Spokesperson, November 8, 2011

On November 8, 2011, Secretary Clinton called on the world to join the United States in working to achieve the goal of an AIDS-free generation during an address at the National Institutes of Health in Bethesda, Maryland. An AIDS-free generation means that virtually no children are born with the virus; that as these children become teenagers and adults, they are at a far lower risk of becoming infected than they would be today, thanks to a wide range of prevention tools; and finally that if they do acquire HIV, they have access to treatment that helps prevent them from developing AIDS and passing the virus to others.

CRS LogoSynthetic Drugs: Overview and Issues for Congress. Congressional Research Service, Library of Congress. Lisa N. Sacco and Kristen M. Finklea. October 28, 2011.

Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, the 112th Congress has demonstrated a renewed concern with the issue.

Safer, Faster, Cheaper: Improving Clinical Trials and Regulatory Pathways to Fight Neglected Diseases. Center for Global Development. Thomas Bollyky. October 31, 2011.

The report of the Working Group on Clinical Trials and Regulatory Pathways provides practical policy recommendations to help provide better, safer, and cheaper medicine and treatment to the 1 billion people suffering from neglected diseases.


Global Health and the New Bottom Billion: What Do Shifts in Global Poverty and the Global Disease Burden Mean for GAVI and the Global Fund? Center for Global Development. Amanda Glassman et al. October 27, 2011.

After a decade of rapid growth in average incomes, many countries have reached middle-income status. At the same time, however, poverty has not fallen so dramatically; as a result, most of the world’s poor now live in middle-income countries (MICs). In fact, up to a billion poor people, or a new bottom billion, live not in the world’s poorest countries but in MICs. As the global distribution of poverty has shifted to middle-income countries, so has the global disease burden. The paper examines the implications of this for global health efforts and recommends a tailored middle-income strategy for global health funders. The paper describes trends in the global distribution of poverty, preventable infectious diseases, and health aid response to date; revisits the rationale for health aid through agencies like GAVI and the Global Fund; and proposes a new MIC strategy and components, concluding with recommendations.


Health Insurance is Good For Your Health. Jenny Li Fowler. Harvard Kennedy School, November 3, 2011

Americans are more likely to seek care, follow doctors’ advice and feel better when provided access to health care insurance. That’s the finding in a new Harvard Kennedy School (HKS) Faculty Working Paper co-authored by HKS Professor Joseph Newhouse. “The Oregon Health Insurance Experiment: Evidence from the First Year,” utilizes data from the 2008 Oregon Medicaid Lottery to discern usage patterns after about one year of insurance coverage. It presents comparisons of outcomes between the treatment group (those selected by the lottery) and the control group (those not selected and therefore unable to apply for Medicaid).


Breast Cancer– Living with the Disease, Part 2. The Century Foundation, October 31, 2011

Below, Amy Berman describes her recent journey through our health care system as “eye-opening.”  In part 1 of this post, she explained why she decided on palliative treatment for breast cancer, rejecting aggressive procedures such as mastectomy and chemo. A year after her diagnosis, she remains comfortable with her decision: “The likelihood is that I will live as long– if not longer–than if I had made another choice.” In fact, studies of palliative and hospice care suggest that patients who choose these alternatives suffer less stress, and as a result, may well outlive other terminal patients.


Why Cancer Patients Can’t Wait: “It Can Mean the Difference Between Curing Your Cancer and Not” from White House.gov Blog Feed by Colleen Curtis. November 1, 2011

President Obama today signed an executive order that directs the FDA to step up work to reduce the drug shortages and protect consumers. (…) The President’s action means that drug companies will be required to let the FDA know earlier about the potential for drug shortages so that they can respond successfully.

This entry was posted in Environment & Energy, Foreign Policy and tagged , , , , , , , , , , , , , . Bookmark the permalink.

Comments are closed.